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Abstract
Background: A cost-utility study of a human papilloma virus (HPV) vaccine requires that the utility weights for
HPV-related health states (i.e., cervical intraepithelial neoplasia (CIN), cervical cancer, and condyloma) be evaluated. The
aim of the present study was to determine the utility weights for HPV-related health states.
Methods: Hypothetical standardised health states related to HPV were developed based on patient education material
and previous publications. To fully reflect disease progression from diagnosis to prognosis, each health state comprised
four parts (diagnosis, symptoms, treatment, and progression and prognosis). Nine-hundred members from the Korean
general population evaluated the HPV-related health states using a visual analogue scale (VAS) and a standard gamble
(SG) approach, which were administered face-to-face via computer-assisted interview. The mean utility values were
calculated for each HPV-related health state.
Results: According to the VAS, the highest utility (0.73) was HPV-positive status, followed by condyloma (0.66), and CIN
grade I (0.61). The lowest utility (0.18) was cervical cancer requiring chemotherapy without surgery, followed by cervical
cancer requiring chemoradiation therapy (0.42). SG revealed that the highest utility (0.83) was HPV-positive
status, followed by condyloma (0.78), and CIN grade I (0.77). The lowest utility (0.43) was cervical cancer requiring
chemotherapy without surgery, followed by cervical cancer requiring chemoradiation therapy (0.60).
Conclusions: This study was based on a large sample derived from the general Korean population; therefore,
the calculated utility weights might be useful for evaluating the economic benefit of cancer screening and HPV
vaccination programs.
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Background
Cervical cancer is the fourth most common cancer among
women world-wide; indeed, there were an estimated
266,000 deaths due to cervical cancer in 2012, accounting
for 7.5% of all female cancer deaths [1]. Persistent infec-
tion with human papillomavirus (HPV), especially HPV
types 16 and 18, is a risk factor of cervical cancer. Further-
more, HPV causes cervical intraepithelial neoplasia (CIN),
anal, penile, vaginal, vulvar, and head/neck cancers,
anogenital warts, and recurrent respiratory papilloma-
toses, leading to deaths in both genders [2].
The HPV vaccine was developed to prevent HPV.
Many clinical trials show the efficacy of the HPV vaccine
in this regard; it also prevents precancerous lesions and
genital warts [3–8]. From an economic perspective,
cost-effectiveness analyses continuously show that HPV
vaccination of preadolescent girls and boys is good
value for money [9]. Thus, many countries are imple-
menting HPV vaccine programs at the national level; it
is suggested that the HPV vaccination should be en-
couraged to reduce the overall burden of HPV-related
disease [10].
When evaluating the efficacy of treatments for HPV-
related diseases, both the clinical outcome and the
health-related quality of life (HRQOL) should be taken
into account. Several indicators of disease burden have
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been used, including quality adjusted life years (QALYs),
which combines the number of years lived by an individ-
ual with their HRQOL. QALYs are used primarily to
correct a patient’s life expectancy based on the HRQOL
they are predicted to experience throughout their life-
time (or part of it) [11]. QALYs are calculated by multi-
plying the length of time spent in a particular health
state by the utility weight associated with that health
state [12]. Thus, utility weights (or health utilities) are
needed to calculate QALYs.
In particular, the HRQOL associated with HPV-related
diseases such as cervical cancer needs to be assessed in
light of increasing survival rates. For this reason, both
cost-effectiveness and cost-utility studies are needed. To
carry out cost-utility studies of HPV-related diseases,
their utility weights must be calculated according to
disease severity. Although some studies determined the
utility weight for cervical cancer according to health
state reflecting patient preferences [13–16], few studies
have examined how members of the general population
evaluate their own preferences in terms of cervical
cancer or precancerous lesions [17, 18]. The utility
weight for HPV-related diseases reflecting preferences
of the general population is much more in need in
various countries, because the perspectives of the general
population provide more relevant information for compara-
tive assessments of health interventions [19]. In addition,
guidelines for economic evaluation of pharmaceuticals in
Korea placed more emphasis on societal perspective than
provider’s perspective or patients’ perspective [20].
Therefore, the aim of the present study was to determine
the utility weights for HPV-related health states based on
data derived from a sample of the general Korean popula-
tion. These results will be used to perform a cost-utility




The target population comprised adults (≥19 years) living
in Korea. A total of 900 representative individuals were ran-
domly selected from this target population using a multi-
stage stratified quota method. A sample quota was assigned
to each of the 15 regions of Korea according to population
and socio-demographic factors, including gender, age, and
education level (as defined by the resident registration data
(June 2013), available from the Ministry of Administration
and Security, South Korea). The participants were recruited
in the street along with quotas.
HPV-related health states
A draft of the standardised HPV-related health states
was created by two investigators (M Ock and MW Jo)
based on patient education materials provided by Asan
Medical Center (AMC), and on data from previous studies
[13, 17]. One gynaecologic oncologist from AMC (Park
JY) reviewed and modified the draft. Each HPV-related
health state was designed to reflect a hypothetical sce-
nario: HPV-positive status; CIN grade I; CIN grade II/
III; cervical cancer requiring simple or radical hyster-
ectomy; cervical cancer requiring radical hysterectomy
and subsequent radiotherapy (and chemotherapy); cervical
cancer requiring chemoradiation therapy; cervical cancer
requiring chemotherapy without surgery; and condyloma
(genital warts [condyloma acuminatum]) (Table 1). Each
hypothetical scenario comprised four parts: diagnosis,
symptoms, treatment, and disease progression and progno-
sis. The scenarios included diagnostic procedures, common
physical side effects of treatment, emotional aspects of
treatment, and information related to the possibility of
complete recovery and 5-year survival rates. All eight
hypothetical scenarios for the HPV-related health states
are described in detail in Additional file 1.
Interviews
This study was approved by the institutional review board
of AMC (S2014-1396-000) and all respondents consented
to participating in the study. The survey was conducted
using face-to-face computer-assisted interviews at respon-
dents’ home. The interviewers were fully trained with re-
spect to HPV-related health states and undertook both
evaluation methods: a visual analogue scale (VAS) and a
standard gamble (SG) approach. All interviewers practiced
in pairs before conducting the field survey. In total, the in-
terviewers received about 2.5 h of training.
Participants were initially asked about their gender,
age, and educational level. Next, we elicited participants’
preference using two valuation methods: VAS and SG.
We asked participants to imagine themselves in the
HPV-related health states. In the case of female-specific
health states, such as cervical cancer and CIN, we made
male participants imagine a woman they were close to,
such as mother or wife, suffering from these health
states. Participants evaluated each of five health states,
Table 1 Eight hypothetical human papilloma virus-related
health states
Number Scenario
1 Human papilloma virus positive state
2 Cervical intraepithelial neoplasia grade I
3 Cervical intraepithelial neoplasia grade II/III
4 Cervical cancer requiring simple or radical hysterectomy
5 Cervical cancer requiring radical hysterectomy and subsequent
radiotherapy (and chemotherapy)
6 Cervical cancer requiring chemoradiation therapy
7 Cervical cancer requiring chemotherapy without surgery
8 Condyloma (genital warts [condyloma acuminatum])
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one of which was being dead, on a VAS scale. The other
four health states were randomly selected from the eight
hypothetical health states. Being dead state was the last
scenario to be rated on the VAS scale. Each participant
consecutively evaluated health states using the SG ap-
proach. Again five health states were randomly selected
from the eight hypothetical states. The health states for
the SG might or might not overlap with those of the
VAS. After the two rounds of valuation, the participants
were asked about other socio-demographic factors, such
as employment and income. They were also asked
whether they had undertaken an ambulatory care visit
within the past 2 weeks, been hospitalised during the
last 12 months, or had any morbidities. We defined
morbidity as the presence of any disease in the partici-
pants and a list of diseases was not specifically provided.
Visual aids were used to help respondents understand
the questions. The procedure of computer-assisted per-
sonal interviewing is available in the Additional file 2.
Valuation methods
We used VAS and SG as valuation methods. For the
VAS, the respondents were asked to rate health states on
a scale from 0 to 100, with 0 representing the worst im-
aginable health and 100 indicating the best imaginable
health.
For the SG, respondents were asked to make a choice
between two health states (one state was a selected
hypothetical scenario and the other was death). The
respondents were then asked to choose between the
following: they could remain in the hypothetical health
state, ‘i’, for the rest of their life-time or they could receive
treatment that may either restore them to full health (prob-
ability ‘p’) or immediately kill them (probability ‘1-p’). The
subject continues to make choices until the preference for
the two choices becomes equal. The minimum probability
interval was 5%. The chances of achieving the best outcome
started at 50%, and increased or decreased by 5% according
to the individual’s response.
Data analysis
First, descriptive analyses of the socio-demographic factors
were performed. Next, the utility weights for each of the
health states were calculated. To ensure that data from
respondents who understood the valuation methods were
included, 42 respondents with outlier VAS values for being
dead (≥21) were excluded from the analysis, in which the
methodology of exclusion was adapted from previous stud-
ies [13, 17]. The median of VAS value for being dead was 3
and its interquartile range was 8. One respondent even
rated 99 for being dead.
For the VAS, the utility weight for each health state
was calculated as follows: VAS value for the health state/
100, where the VAS value for being dead was 0. However, if
the VAS value for being dead was not 0, the following for-
mula was used: (VAS value for the health state – the VAS
value for being dead)/(100 – VAS value for being dead).
For the SG, the utility weights for each health state dif-
fered depending on the answer to the question that com-
pared a particular health state with being dead. That is, the
utility weight for each health state was calculated as the
possibility of restoring full health (if the health state was
regarded as a better option than being dead). The utility
weight for each health state was calculated as follows: -
possibility of restoring full health/(1- possibility of re-
storing full health), if the health state was regarded as
worse than being dead. However, the utility weight for
any health state that was considered worse than being
dead was censored at zero.
The mean values for the utility weights according to
socio-demographic factors and clinical information were
compared using Student’s t-test and analysis of variance.
Furthermore, we applied a linear regression regarding
the utility weights from the VAS and SG as the dependent
variable. We treated the socio-demographic factors and
clinical information as independent variable. We also
regarded the HPV-related health states as independent
variable and created them as dummy variables with
‘HPV-positive status’ as the reference.
All statistical analyses were conducted using SPSS
software (v21.0) and Stata 13.1 software (StataCorp,
College Station, TX). A P-value < 0.05 was considered
statistically significant.
Results
Demographic characteristics of the study subjects
Nine-hundred respondents were interviewed. The mean
age of the respondents was 45.3 (standard deviation: 14.1)
years, and 49.4% were male. The clinical and demographic
characteristics of the respondents are shown in Table 2.
VAS and SG data
VAS: the highest utility weight (0.73) was assigned to
HPV-positive status, followed by condyloma (0.66), and
CIN grade I (0.61). The lowest utility weight (0.18) was
assigned to cervical cancer requiring chemotherapy without
surgery, followed by cervical cancer requiring chemoradia-
tion therapy (0.42), and cervical cancer requiring radical
hysterectomy and subsequent radiotherapy (and chemo-
therapy) (0.50). The difference between the utility weights
for the two CIN states was only 0.01 (Table 3).
SG: The highest utility weight (0.83) was assigned to
HPV-positive status, followed by condyloma (0.78), and
CIN I (0.774). The lowest utility weight (0.43) was assigned
to cervical cancer requiring chemotherapy without surgery,
followed by cervical cancer requiring chemoradiation ther-
apy (0.60), and cervical cancer requiring radical hysterec-
tomy and subsequent radiotherapy (and chemotherapy)
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(0.65). The difference between the utility weights for the
two CIN states was only 0.001 (Table 3).
For each health state, the mean utility weight calcu-
lated from the SG was greater than that calculated from
the VAS. The difference in the utility weight calculated
from the two methods was the smallest for HPV-positive
status (0.10) and greatest for cervical cancer requiring
chemotherapy without surgery (0.25). The mean utility
weights calculated from the VAS and SG did not differ
significantly according to gender, age, or educational
level (Table 4). However, the respondents with a low in-
come tended to score lower than those with a high in-
come in both the VAS and SG, in general. For the
clinical information, the particular trends could not be
noticed in the utility weights from VAS and SG.
Table 5 shows results from the multivariable linear
regression method. The health states were main rele-
vant factors associated with the utility weights from the
VAS and SG. After adjusting the respondents’ socio-
demographic factors and clinical information, the utility
weight for cervical cancer requiring chemotherapy with-
out surgery were 0.554 lower than HPV-positive status in
the VAS and 0.400 lower in the SG. In addition, the utility
weights from respondents with a high income (>5.0
million won) were significantly higher than those with a
low income (less than 2.5 million won) in both VAS
and SG.
Discussion
Here, we calculated the societal utility weights for eight
hypothetical HPV-related health states based on the
responses of 900 individuals selected from the general
South Korean population. The main strength of this
study is the fact that we evaluated the preferences of a
relatively large sample (n = 900). A major question arises
with respect to economic evaluation of healthcare pro-
grams: whose judgments should be used to define pref-
erences? The general consensus is that the preferences
of the general population should carry more weight than
those of patients or healthcare professionals [21]. Other
studies have examined the preferences of individuals
with an abnormal Pap test [13], or the preferences of
women alone [14, 15, 17]. Therefore, the results of the
present study might be more appropriate for economic
evaluation of cancer screening and HPV vaccination pro-
grams, for which the target population will be the gen-
eral tax-paying public.
To examine the preferences of the general population,
the sample group was presented with several different
scenarios regarding HPV-related health states, which
were designed to encompass diagnosis, treatment, and
disease progression and prognosis. These scenarios were
based on a literature review [13, 17] and also on patient
education materials. When evaluating the preferences of
the general population, these scenarios need to be ex-
plained in a manner than can be understood by all. Thus,
the use of patient education material enabled people to
better understand the different HPV-related health states.
In particular, we included information related to progno-
sis, including survival rates and the chance of a complete
cure. Because prognosis may play an important role in de-
termining the utility weights of different diseases [13], the
results of the present study may better reflect the prefer-
ences of the general population.
We used a VAS scale and an SG approach to determine
the preferences of the study group for different HPV-
related health states. The SG is a method of measuring
respondents’ preferences under conditions of uncertainty,
and is based directly on the von Neumann-Morgenstern
utility theory, which is regarded as the gold standard for
modelling rational behaviour in the context of uncertainty
[22]. Furthermore, we felt that SG was more appropriate
than any other evaluation method, in particular time trade-
off (TTO), because assumptions based on “the rest of your
life-time” are not appropriate in some scenarios; for ex-
ample, “Cervical cancer requiring chemotherapy without
Table 2 Socio-demographic characteristics and clinical information
for the study participants
Characteristic Number Percent
Gender Male 445 49.4
Female 455 50.6





Education level Elementary school or below 29 3.2
Middle school 80 8.9
High school 586 65.1
College or above 205 22.8





Less than 2.5 million won 201 22.3
2.5–5.0 million won 591 65.7
>5.0 million won 108 12.0
Ambulatory care visit in
the past 2 weeks
Yes 124 13.8
No 776 86.2




Morbiditya Yes 122 13.6
No 778 86.4
aDefined as the presence of any disease in the participants
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Table 3 Utility weights derived from the VAS and SG












VAS N 415 475 431 439 415 412 418 427
Mean 0.73 0.61 0.60 0.59 0.50 0.42 0.18 0.66
SD 0.15 0.17 0.18 0.19 0.18 0.15 0.15 0.18
Median 0.78 0.64 0.63 0.61 0.53 0.43 0.14 0.70
1st quartile 0.67 0.50 0.49 0.47 0.37 0.33 0.07 0.55
3rd quartile 0.84 0.72 0.73 0.72 0.63 0.50 0.25 0.80
SG N 535 538 535 542 542 538 544 516
Mean 0.83 0.774 0.773 0.71 0.65 0.60 0.43 0.78
SD 0.26 0.27 0.28 0.32 0.31 0.28 0.32 0.29
Median 0.95 0.90 0.90 0.85 0.78 0.70 0.40 0.90
1st quartile 0.80 0.70 0.70 0.45 0.40 0.35 0.10 0.70
3rd quartile 1.00 0.95 0.95 0.95 0.90 0.80 0.70 1.00



















surgery” has a 1 year survival rate of < 10%. The VAS does
not allow a trade-off between different health states, and so
is commonly regarded as lacking any theoretical basis when
compared with choice-based methods such as SG and
TTO [23]; however, the VAS is easy to understand. Thus, it
is widely used in evaluation studies. Furthermore, there is
no single preferred method of evaluation that is appropriate
under all circumstances [24]. Therefore, it is meaning-
ful to compare the results obtained from the VAS and
SG methods.
The utility weights calculated from the VAS and SG in
the present study were very consistent in terms of
ordinal rankings. For example, the utility of HPV-positive
status was 0.73 in the VAS and 0.83 in SG, and that for cer-
vical cancer requiring chemotherapy without surgery was
0.18 in the VAS and 0.43 in SG. Although not directly com-
parable, the utility weights for HPV-related health states
calculated herein (particularly those for less-serious health
states) were lower than those calculated by previous studies.
Kuppermann et al. reported a TTO utility of 0.909 for
HPV-positive status, and 0.666 for invasive cervical cancer
requiring radical hysterectomy or radiation and chemother-
apy [13], whereas Melnikow et al. reported an SG utility of
0.92 for a low-grade abnormal Pap smear with cone biopsy
[15]. Furthermore, Howard et al. reported an SG utility of
0.935 for HPV-positive requiring colposcopy, biopsy, and
treatment [14], and Jewell EL et al. reported a TTO utility
of 0.96 for minimally invasive cervical cancer requiring rad-
ical hysterectomy [17]. Marcellusi A et al. reported a TTO
utility of 0.83, 0.81, and 0.58 for CIN grade I, CIN grade II/
III, and cervical cancer, respectively [18]. The reason for
these differences may be the detailed health state scenarios
described in the present study; we provided respondents
with a relatively in-depth description of the less severe
HPV-related health states, including information about
prognosis. This may have made respondents more fearful
of such health states. In addition, there may be cultural
differences in the evaluations of HPV-related health states
because HPV is a sexually transmitted virus that carries
considerable social stigma [25].
Another remarkable issue in this study would be gender
differences in the utility weights of HPV-related health
states. Utility weights for gender-specific health states, such
as cervical cancer, may differ by gender, but there were no
significant differences in the estimated utility weights for
HPV-related health states by gender in this study. The
Table 4 Utility weights derived from the VAS and SG according to socio-demographic factors and clinical information
Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5 Scenario 6 Scenario 7 Scenario 8
VAS SG VAS SG VAS SG VAS SG VAS SG VAS SG VAS SG VAS SG
Gender Male 0.74 0.84 0.60 0.78 0.59 0.77 0.59 0.70 0.50 0.64 0.41 0.59 0.18 0.41 0.67 0.78
Female 0.73 0.82 0.61 0.77 0.61 0.77 0.59 0.71 0.51 0.67 0.43 0.60 0.18 0.44 0.66 0.77
Age group 19–29 0.73 0.85 0.61 0.78 0.60 0.81 0.60 0.76 0.46 0.70 0.43 0.65 0.17 0.44 0.63 0.82
30–39 0.76 0.84 0.59 0.76 0.60 0.80 0.59 0.71 0.52 0.64 0.43 0.57 0.20 0.43 0.67 0.77
40–49 0.72 0.85 0.62 0.78 0.62 0.75 0.60 0.67 0.50 0.63 0.41 0.58 0.18 0.42 0.66 0.76
50–59 0.75 0.84 0.61 0.80 0.58 0.78 0.57 0.73 0.51 0.69 0.42 0.61 0.19 0.45 0.66 0.82
≥60 0.71 0.79 0.61 0.75 0.62 0.73 0.60 0.67 0.52 0.62 0.42 0.59 0.17 0.39 0.69 0.72
Education level High school or below 0.73 0.83 0.61 0.77 0.61 0.77 0.59 0.69 0.51 0.66 0.43 0.60 0.18 0.42 0.67 0.77
College or above 0.76 0.84 0.61 0.80 0.60 0.79 0.59 0.74 0.48 0.61 0.40 0.59 0.17 0.43 0.66 0.80
Occupation Non-manual 0.77* 0.88 0.63 0.77 0.62 0.77 0.60 0.71* 0.50 0.60 0.42 0.56 0.17 0.37 0.67 0.81
Manual 0.73* 0.82 0.59 0.77 0.61 0.76 0.58 0.67* 0.50 0.64 0.42 0.60 0.18 0.43 0.67 0.77
Other 0.71* 0.82 0.62 0.78 0.59 0.80 0.60 0.75* 0.52 0.69 0.42 0.62 0.18 0.45 0.66 0.77
Monthly income Less than 2.5 million won 0.71* 0.78** 0.59 0.74 0.61 0.75 0.59 0.69* 0.51 0.65* 0.40 0.59 0.16 0.41 0.69 0.72**
2.5–5.0 million won 0.73* 0.84** 0.61 0.77 0.59 0.78 0.59 0.69* 0.50 0.64* 0.43 0.60 0.18 0.42 0.65 0.78**




Yes 0.74 0.78* 0.62 0.78 0.58 0.77 0.61 0.76 0.52 0.66 0.41 0.60 0.20 0.37 0.71* 0.71
No 0.73 0.84* 0.61 0.77 0.61 0.77 0.59 0.70 0.50 0.65 0.42 0.60 0.18 0.43 0.66* 0.78
Hospitalised in
past 12 months
Yes 0.74 0.90 0.57 0.84 0.61 0.83 0.68 0.84 0.59 0.61 0.51* 0.61 0.23 0.44 0.62 0.82
No 0.73 0.83 0.61 0.77 0.60 0.77 0.59 0.70 0.50 0.65 0.42* 0.60 0.18 0.42 0.66 0.78
Morbidity Yes 0.77 0.86 0.64 0.79 0.63 0.78 0.59 0.73 0.49 0.59 0.38* 0.62 0.14* 0.43 0.72* 0.77
No 0.73 0.83 0.60 0.77 0.60 0.77 0.59 0.70 0.51 0.66 0.43* 0.59 0.19* 0.42 0.65* 0.78
VAS visual analogue scale, SG standard gamble
*P-value < 0.05; **P-value < 0.01
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Table 5 Multivariable regression model for factors influencing the utility weights
Factors Visual analogue scale Standard gamble
Coefficient 95% CI coefficient Coefficient 95% CI coefficient
Lower Upper Lower Upper
Gender
Men Ref Ref
Women 0.006 -0.007 0.018 -0.008 -0.026 0.011
Age (years)
19–29 Ref Ref
30–39 0.015 -0.004 0.034 -0.022 -0.050 0.007
40–49 0.005 -0.014 0.024 -0.038** -0.066 -0.011
50–59 0.004 -0.016 0.023 -0.008 -0.036 0.021
≥60 0.011 -0.010 0.032 -0.075** -0.105 -0.044
Education level
High school or below Ref Ref
College above -0.015* -0.031 0.000 0.003 -0.019 0.026
Occupation
Non-manual Ref Ref
Manual -0.014 -0.031 0.003 0.019 -0.006 0.045
Other -0.014 -0.033 0.005 0.054** 0.026 0.082
Monthly income
Less than 2.5 million won Ref Ref
2.5–5.0 million won 0.005 -0.011 0.021 -0.001 -0.024 0.022
>5.0 million won 0.034** 0.011 0.056 0.069** 0.036 0.102
Ambulatory care visit in past 2 weeks
Yes Ref Ref
No -0.011 -0.030 0.009 0.025 -0.003 0.054
Hospitalized in past 12 month
Yes Ref
No -0.025 -0.061 0.010 -0.036 -0.091 0.018
Morbidity
Yes Ref Ref
No 0.001 -0.019 0.022 -0.030 -0.060 0.000
Scenario
1. HPV-positive Ref
2. CIN grade I -0.126** -0.148 -0.104 -0.056** -0.090 -0.022
3. CIN grade II/III -0.131** -0.153 -0.108 -0.057** -0.091 -0.023
4. Cervical Cancer (simple or radical hysterectomy) -0.144** -0.166 -0.121 -0.128** -0.162 -0.095
5. Cervical cancer (radical hysterectomy +
radiotherapy + (chemotherapy))
-0.231** -0.253 -0.208 -0.178** -0.212 -0.145
6. Cervical cancer (chemoradiation) -0.314** -0.337 -0.291 -0.227** -0.261 -0.194
7. Cervical cancer (chemotherapy) -0.554** -0.577 -0.531 -0.400** -0.434 -0.367
8. Condyloma -0.071** -0.094 -0.048 -0.059** -0.092 -0.025
CI confidence interval, HPV human papilloma virus, CIN cervical intraepithelial neoplasia
*P-value < 0.05; **P-value < 0.01
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reason for this finding is unclear, but it may be that male
participants evaluated female-specific health states in this
study as seriously as female participants did. In another
study, utility weight lost due to anogenital warts was more
prominent among women than men [18]. Furthermore, it
seemed that the way of eliciting male participants’ prefer-
ence regarding female-specific health states may influence
gender differences. In this study, we asked male participants
to imagine their mother or wife in the female-specific
health states, rather than themselves in the HPV-related
health states. However, further research will be needed to
verify these assumptions.
The utility weights for HPV-related health states calcu-
lated in the present study are lower than those calculated in
an indirect evaluation study performed in South Korea
[10]. Kim et al. used a generic HRQOL instrument, the
EQ-5D, to measure the HRQOL of 452 patients with CIN
or cervical cancer [10]. According to that study, the highest
utility weight was assigned to CIN grade I (0.937), followed
by CIN grade II/III (0.933), cervical cancer (0.874), and re-
current cervical cancer (0.784). However, there are two
points of concern with respect to the interpretation of those
results. First, although determining the preferences of pa-
tients may reflect the actual utility, dropouts due to death
or loss to follow-up and/or adaptation to disease can affect
HRQOL [26]. Second, the EQ-5D, which comprises five
dimensions from the HRQOL, does not fully reflect the
health state of patients with CIN or cervical cancer. Thus,
Kim et al. may have overestimated the utility weights [10].
There are several limitations in this study. First, we did
not determine the total number of people contacted for the
survey and thus we could not estimate the survey response
rate. This limitation can restrict the representativeness of
this study. Second, we did not ask each respondent evaluate
all eight HPV-related health states. The reason for this was
to minimise cognitive loading. If each respondent had to as-
sess the utility weight for all eight HPV-related health
states, the differences between the utility weights for each
health state may be more marked. Third, there could have
been an interviewer effect in the process of survey, which
was conducted using face-to-face computer-assisted inter-
views. Although we trained interviewers not to have an ef-
fect on the response of survey participants, interviewers
could have unintentionally affected the preferences of par-
ticipants in the process of explaining HPV-related health
states. Fourth, the generalizability of this study may be lim-
ited to other countries due to racial or cultural differences.
Further research targeting the general public from other
countries is necessary.
Conclusion
We obtained societal utility weights for HPV-related
health states from 900 respondents drawn from the gen-
eral population. These results will be useful for analysing
the cost-effectiveness of healthcare interventions, such as
cancer screening and vaccination programs for HPV-
related diseases.
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